IceCure Medical (ICCM) updates ProSense endometriosis pain data via 6-K filing

Rhea-AI Filing Summary

IceCure Medical Ltd. submitted a Form 6-K to furnish a new press release dated September 4, 2025. The release, titled “IceCure’s ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy,” highlights results related to use of the company’s ProSense® system for abdominal wall endometriosis pain and describes high procedural efficacy.

Except for its fourth paragraph, the press release is incorporated by reference into IceCure’s existing shelf and equity compensation registration statements on Form F-3 and Form S-8, making the clinical and procedural information part of those U.S. securities offerings documentation going forward, unless later filings replace it.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: September 2025

Commission File Number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F             ☐ Form 40-F

CONTENTS

On September 4, 2025, IceCure Medical Ltd. (the “Company”) issued a press release titled “IceCure’s ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy,” a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K. 

The press release attached herewith as Exhibit 99.1, excluding the fourth paragraph thereof, is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-258660 and 333-267272) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.
99.1		Press release dated September 4, 2025 titled “IceCure’s ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ICECURE MEDICAL LTD.
Date: September 4, 2025	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

2

FAQ

What did IceCure Medical (ICCM) report in its latest Form 6-K?

IceCure Medical filed a Form 6-K to furnish a press release dated September 4, 2025 titled “IceCure’s ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy.”

What is the focus of IceCure Medical’s September 4, 2025 press release?

The press release discusses IceCure’s ProSense® system and reports that it substantially reduces abdominal wall endometriosis pain while showing high procedural efficacy.

How is the new ProSense endometriosis press release used in IceCure Medical’s U.S. registrations?

The press release, excluding its fourth paragraph, is incorporated by reference into IceCure Medical’s Registration Statements on Form F-3 and Form S-8, becoming part of those filings from the date of the Form 6-K.

Which specific registration statements does IceCure Medical’s press release update?

The press release is incorporated by reference into Form F-3 Registration Nos. 333-258660 and 333-267272 and Form S-8 Registration Nos. 333-270982, 333-264578, 333-262620 and 333-281587.

Does the Form 6-K indicate who signed the report for IceCure Medical?

Yes. The Form 6-K was signed on behalf of IceCure Medical Ltd. by Chief Executive Officer Eyal Shamir on September 4, 2025.

Why is a Form 6-K important for IceCure Medical investors?

Form 6-K updates investors on significant information for a foreign private issuer; here, it makes the ProSense® abdominal wall endometriosis pain and procedural efficacy press release part of IceCure’s U.S. registration statements.